Table 1.

Clinical characteristics of SARS-CoV-2 infected patients treated with conestat alfa.

Characteristicsa	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
BMI	27.7	28.4	22.4	31.2	22.6
Smoking (ongoing or recent)	No	Yes	Yes	No	Yes
Comorbidity	CKD, hypertension, hypercholesterolemia, gout	CKD, CVD, diabetes, hypertension, PAD	CVD, hypertension	Asthma, hypertension, hypothyroidism	None
Days from symptom onset to admission	15	4	4	6	7
Days from admission to conestat alfa	1	1	7	1	2
Symptoms	Fever, diarrhea, fatigue, cough, chest pain	Cough, sore throat	Fatigue, diarrhea, muscle ache	Cough, diarrhea, fatigue, muscle ache, dyspnea	Fever, cough, fatigue, dyspnea
Lung involvement, %b	14	18	39	24	11
SOFA score day 0	1	2	2	1	2
NEWS2 score day 0	5	5	9	8	7
SARS-CoV-2 viral load day 0, copies/mL	23,500	36,046,600	1,000	611,900	33,400
Respiratory rate day 0, per minute	21	25	22	22	24
CRP day 0, mg/L	203	235	223	106	31
Ferritin day 0, μg/L	1,280	567	3,736	560	1,805
LDH day 0, U/L	379	466	483	366	584
D-dimer day 0, μg/ml	1.2	4.2	1.0	0.6	1.7
IL-6 day 0, ng/L	60	187	141	55	32
C1INH d0, g/l	0.71	0.45	0.57	0.52	0.64
C1INH d1, g/l	0.71	0.48	0.58	0.53	0.63

CKD, chronic kidney disease; CVD, cardiovascular disease; PAD, peripheral artery disease; BMI, body mass index; SOFA, sepsis-related organ failure assessment score; NEWS2, National Early Warning Score 2; CRP, C-reactive protein; LDH, lactate dehydrogenase; IL-6, interleukin-6.

^aDay 0 denotes the day of first administration.

^bLung involvement was determined from computed tomography scans of the chest.